RESEARCH MONOGRAPH · KDC-MN-176

Ginkgo Biloba

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

69/100

Standardized extracts have real microvascular and modest cognitive effects, but the noise-to-signal in the market is high

Ginkgo biloba leaf extract is one of the most-studied botanicals in clinical research, with hundreds of human trials. The active fraction is the flavonol glycosides (quercetin, kaempferol, isorhamnetin derivatives) and the terpene lactones (ginkgolides A, B, C, J, and bilobalide). The reference standardized extract for most clinical work is EGb 761 (Tebonin/Ginkgold/Schwabe formulation), standardized to 24% flavone glycosides and 6% terpene lactones.

The mechanism is multi-target and reasonably well-mapped. Ginkgolide B is a potent platelet activating factor (PAF) antagonist. The flavonoid fraction provides antioxidant activity. There's mitochondrial bioenergetic modulation, microvascular flow improvements (likely the dominant clinical mechanism for the cognitive effects), and some neurotransmitter modulation. The microcirculatory story is the most solid in animal models and matches the clinical effects best.

Clinical evidence at the EGb 761 dose (240mg daily) is genuinely substantial. Cochrane has reviewed ginkgo for dementia and cognitive impairment multiple times, and the recent reviews (post-2014) are more positive than the older ones, with modest but real cognitive benefits in mild to moderate dementia at 240mg of standardized extract. For healthy adults the cognitive signal is much weaker, with most trials negative or marginal at best.

Peripheral vascular indications (intermittent claudication, tinnitus, vertigo) have moderate evidence, mostly in European clinical use where standardized extracts are regulated as drugs.

Sourcing is the make-or-break issue. EGb 761 is the gold standard with consistent chemistry. Generic ginkgo extracts on the supplement market vary dramatically in ginkgolide and flavonoid content, and some have been shown in third-party testing to have very low actual terpene lactone content compared to label claims. Some adulteration with rutin (to boost apparent flavonoid content) has been documented.

Safety is generally fine but the antiplatelet activity is real, with documented anticoagulant interactions and case reports of bleeding events at high doses with concomitant aspirin or warfarin.

What we like: the standardized extracts have real evidence, the mechanism story is coherent, and the dementia signal is non-trivial. What we dont like: most ginkgo on the supplement market is not the studied material, the quality variability is enormous, and a lot of the marketing for healthy-adult cognition is not supported by the trial data.

Evidence: 72
Mechanism: 75
Reliability: 70
Safety: 75
Sourcing: 55
Value: 65
Signal: 68
Staying power: 70

Plain-language summary Intrigue 52 / 100

Ginkgo biloba is a maidenhair tree leaf extract widely used for cerebral circulation and cognitive function. The ginkgolides and bilobalides are the principal active compounds. Used historically for stroke and dementia. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Maidenhair tree leaf extract

Standardized extract of Ginkgo biloba leaves used for cognitive function and peripheral circulation, characterized by flavonoid glycosides and terpene lactones.

Abstract

Ginkgo biloba is the world's oldest living tree species, with leaves used in traditional Chinese medicine and standardized extracts (EGb 761) marketed in Europe for cognitive impairment and peripheral arterial disease. Active constituents are flavonoid glycosides (24 percent in EGb 761) and terpene lactones (ginkgolides A, B, C; bilobalide; 6 percent). Pharmacology includes platelet activating factor (PAF) antagonism (ginkgolides), MAO inhibition (modest), and antioxidant activity. The clinical evidence base in dementia is mixed (large GEM and GuidAge trials negative); peripheral arterial disease evidence is more positive. Reported research dose ranges in the literature are described in the source publications.

Mechanism of action

Flavonoid glycosides + terpene lactones. PAF antagonism (ginkgolides). MAO inhibition. Antioxidant.

Reported research dose ranges

Reported research dose ranges in the literature.

References

DeKosky ST, et al. Ginkgo biloba for prevention of dementia (GEM). JAMA 2008.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-176

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Ginkgo Biloba

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs